GlassScriptPhysician profile
Brandon L Davis
NPI 1235343187
$6,666.20
in general payments reported to CMS, 2019-2025
26 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $233 · 2021: $396 · 2022: $1,063 · 2023: $1,082 · 2024: $805 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,072.26 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $794.34 | 2022-2025 | Ozurdex |
| Allergan, INC. | $714.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $553.26 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $369.52 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $362.18 | 2023-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec USA, INC. | $350.34 | 2025 | |
| Genentech USA, INC. | $319.34 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $311.87 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $254.76 | 2022-2025 | Syfovre |
| Horizon Therapeutics Plc | $197.99 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.23 | 2019-2020 | |
| Alcon Vision LLC | $151.61 | 2022-2025 | Clareon Panoptix Pro |
| Omeros Corporation | $150.18 | 2019-2020 | |
| Glaukos Corporation | $149.07 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $133.25 | 2025 | Iheezo, Triesence |
| Sun Pharmaceutical Industries INC. | $126.29 | 2023 | Cequa |
| Dompe US, INC. | $119.78 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $105.32 | 2022-2023 | Stellaris |
| Alimera Sciences, INC. | $64.90 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $60.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.95 | 2019-2024 | Xifaxan |
| Optos, INC. | $32.68 | 2021 | |
| Kala Pharmaceuticals, INC. | $26.15 | 2019 | |
| Axsome Therapeutics, INC. | $23.39 | 2025 | Auvelity |
| Neurotech Pharmaceuticals, INC. | $21.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.